Tesamorelin (brand name Egrifta) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It’s FDA-approved specifically for reducing excess abdominal fat (visceral adipose tissue) in HIV-infected patients with lipodystrophy. The 10mg reference likely points to a common vial size for research or compounded formulations, as clinical doses are typically reconstituted from 2mg vials—but 10mg vials exist in peptide research/supplement markets.

Key Facts

Evidence-Based Benefits (from RCTs & Meta-Analyses)

• HIV Lipodystrophy: Phase III trials (e.g., NEJM 2010) showed 15-18% visceral fat reduction after 26 weeks (p<0.001 vs placebo). Sustained with continued use.
• Off-Label/Research:

Side Effects & Risks (from Clinical Data)

Contraindications: Active malignancy, pregnancy (Cat. B), hypersensitivity. Monitor IGF-1 to avoid acromegaly-like effects (>3x ULN).

Dosing Protocol Example (Research/Off-Label, 10mg Vial)

1. Reconstitution: Add 5mL BAC water to 10mg vial → 2mg/mL. Gently swirl (no shake).
2. Administration: 1mL (2mg) SC into abdomen nightly, pre-bed (synergizes natural GH pulse).
3. Cycle: 12-26 weeks on, 4 weeks off. Stack with MK-677 or Ipamorelin? Synergistic in rodent GH studies, but human data sparse.
4. Storage: Lyophilized: room temp <1mo or freeze. Reconstituted: 2-8°C, 14 days.

Legality & Sourcing

• Rx Only in US/EU for HIV use. Off-label/research peptides are gray-area (not for human consumption per FDA).
• Purity matters: HPLC ≥99% ideal. Third-party test via Janoshik or similar.

Data Sources: FDA label, PubMed (e.g., PMID 20089964), clinicaltrials.gov. Not medical advice—consult physician. For lab protocols or custom stacks, provide more details.